British Axial Spondyloarthritis Inception Cohort (BAxSIC): a protocol for a multicentre real-world observational cohort study of early axial spondyloarthritis

被引:1
|
作者
Weddell, Jake [1 ,2 ]
Harrison, Stephanie R. [1 ,2 ,3 ,4 ]
Bennett, Alexander N. [5 ,6 ]
Gaffney, Karl [7 ,8 ]
Jones, Gareth T. [9 ]
Machado, Pedro M. [10 ]
Packham, Jonathan [11 ]
Sengupta, Raj [12 ,13 ]
Zhao, Sizheng Steven [14 ]
Siebert, Stefan [15 ]
Marzo-Ortega, Helena [1 ,2 ]
机构
[1] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, England
[2] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, England
[3] Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, England
[4] Univ Leeds, Leeds Inst Data Analyt, Leeds, England
[5] Imperial Coll, Natl Heart & Lung Inst, Fac Med, London, England
[6] DMRC, Acad Dept Mil Rehabil, Loughborough, England
[7] Univ East Anglia, Norfolk & Norwich Univ Hosp NHS Fdn Trust, Norwich, England
[8] Univ East Anglia, Norwich Med Sch, Norwich, England
[9] Univ Aberdeen, Aberdeen Ctr Arthrit & Musculoskeletal Hlth, Epidemiol Grp, Aberdeen, Scotland
[10] UCL, Ctr Rheumatol, Dept Neuromuscular Dis, London, England
[11] Univ Nottingham, Unit Populat & Lifespan Sci, Nottingham, England
[12] Royal United Hosp, Royal Natl Hosp Rheumat Dis, Bath, England
[13] Univ Bath, Ctr Therapeut Innovat, Dept Life Sci, Bath, England
[14] Univ Manchester, Div Musculoskeletal & Dermatol Sci, Manchester, England
[15] Univ Glasgow, Coll Med Vet & Life Sci, Sch Infect & Immun, Glasgow, Scotland
关键词
axial spondyloarthritis; rheumatology; diagnostic delay; inception cohort; virtual follow-up; ANKYLOSING-SPONDYLITIS; DIAGNOSTIC DELAY; VALIDITY; CRITERIA; PAIN;
D O I
10.1093/rap/rkae087
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives Timely diagnosis remains a challenge in axial SpA (axSpA). In addition, data are scarce on the impact of diagnostic delay and disease progression in affected individuals. The British Axial Spondyloarthritis Inception Cohort (BAxSIC) study aims to investigate the impact of newly diagnosed axSpA, the natural history of the disease and the effect of diagnostic delay on disease outcomes.Methods BAxSIC is a prospective, multicentre, observational study. Eligible participants are adults (>= 16 years of age), with a physician-confirmed diagnosis of axSpA in the 6 months prior to study entry, recruited from secondary and tertiary rheumatology centres in the UK. Participants will be followed up for 3 years, with in-person visits at baseline and 24 months. In addition, patient self-reported assessments will be recorded remotely via the online electronic case report form (eCRF) at 6, 12, 18, 30 and 36 months.Results The first patient was enrolled in BAxSIC in June 2023. Recruitment is currently ongoing and is planned to end in June 2026. Initial results will be available in 2027. Since opening, the trial has undergone two protocol amendments.Conclusion The BAxSIC study is the first inception cohort designed to investigate the impact of diagnostic delay on clinical presentation and long-term functional outcomes in patients with axSpA in the UK. With an innovative, patient-led virtual longitudinal data collection model, data generated from this study will help inform and improve the care of people newly diagnosed with axSpA.Trial registration ClinicalTrials.gov (http://clinicaltrials.gov), NCT05676775. What does this mean for patients?Axial spondyloarthritis (axSpA) is often diagnosed following many years of symptoms, with an estimated average of 8.5 years from the first symptoms of back pain to diagnosis. Currently there is little research into the impact of this 'diagnostic delay' on initial presentation, disease course and long-term effects in axSpA. The British Axial Spondyloarthritis Inception Cohort (BAxSIC) study aims to investigate the impact of diagnostic delay on patients with newly diagnosed axSpA. BAxSIC is an observational study recruiting patients in the UK with a new diagnosis of axSpA. Patients will be reviewed in person at initial recruitment and at 24 months. In addition, patients will complete online questionnaires about their health and well-being at 6, 12, 18 and 36 months. The study aims to recruit a minimum of 500 patients and participants will be followed up for 36 months. BAxSIC is the first large study in the UK to investigate the impact of diagnostic delay on patients with axSpA. An innovative, longitudinal, online-based data collection model will allow us to collect data in a way that is minimally disruptive to participants. Data from this study will help to improve long-term patient care.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Pregnancy rates and outcomes in early axial spondyloarthritis: An analysis of the DESIR cohort
    Pons, Marion
    Dougados, Maxime
    Costedoat-Chalumeau, Nathalie
    Briot, Karine
    Goupille, Philippe
    Roux, Christian
    Molto, Anna
    JOINT BONE SPINE, 2021, 88 (02)
  • [42] Pregnancy Rates and Outcomes in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort
    Pons, Marion
    Costedoat-Chalumeau, Nathalie
    Briot, Karine
    Goupille, Philippe
    Roux, Christian
    Dougados, Maxime
    Molto, Anna
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [43] PREGNANCY RATES AND OUTCOMES IN EARLY AXIAL SPONDYLOARTHRITIS: ANALYSIS OF THE DESIR COHORT
    Pons, Marion
    Costedoat-Chalumeau, Nathalie
    Briot, Karine
    Goupille, Philippe
    Roux, Christian
    Dougados, Maxime
    Molto, Anna
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1252 - 1252
  • [44] REAL-WORLD EXPERIENCE OF SECUKINUMAB FOR AXIAL SPONDYLOARTHRITIS: SPECIFIC POPULATION CHARACTERISTICS
    Emperiale, Valentina
    Campos Esteban, Jose
    Merino Argumanez, Carolina
    Bachiller-Corral, Javier
    Valero, Marta
    Joven-Ibanez, Beatriz
    Martin, Maria
    Perez Gomez, Ana
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1812 - 1813
  • [45] REAL-WORLD EFFECTIVENESS AND SAFETYOF SECUKINUMAB IN AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS
    Astigarraga Urquia, Uxue
    Gomez, Marta Lopez I.
    Ibarrola, Libe
    Pineiro, Irene
    Mendizabal, Javier
    Sada Urdameneta, Guillen
    Del Val Del Amo, Natividad
    Paniagua Zudaire, Inmaculada
    Garrido Courel, Laura
    Fito Manteca, Concepcion
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2023, 29 : S104 - S105
  • [46] Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis
    Weddell, Jake
    Din, Naw Ra Aung
    Harrison, Stephanie R.
    Michelena, Xabier
    McGonagle, Dennis
    Barr, Andrew
    Vandevelde, Claire
    Freeston, Jane
    Marzo-Ortega, Helena
    RHEUMATOLOGY ADVANCES IN PRACTICE, 2023, 8 (01)
  • [47] Lifestyle Factors and Disease Activity Over Time in Early Axial Spondyloarthritis: The SPondyloArthritis Caught Early (SPACE) Cohort
    Exarchou, Sofia
    Turesson, Carl
    Lindstrom, Ulf
    Ramonda, Roberta
    Landewe, Robert B.
    Dagfinrud, Hanne
    van Gaalen, Floris
    van der Heijde, Desiree
    Jacobsson, Lennart T.
    JOURNAL OF RHEUMATOLOGY, 2022, 49 (04) : 365 - 372
  • [48] IMMUNOGENICITY AND LOSS OF RESPONSE TO TNF INHIBITORS IN AXIAL SPONDYLOARTHRITIS: RESULTS FROM AN OBSERVATIONAL COHORT STUDY
    Ancuta, C. I.
    Pomirleanu, C.
    Paiu, R.
    Strugariu, G.
    Petrariu, L.
    Ancuta, E.
    Iordache, C.
    Chirieac, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1003 - 1003
  • [49] Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study
    Ganapati, Arvind
    Gowri, Mahasampath
    Antonisamy, Belavendra
    Danda, Debashish
    CLINICAL RHEUMATOLOGY, 2021, 40 (05) : 1871 - 1879
  • [50] Combination of methotrexate and sulfasalazine is an efficacious option for axial spondyloarthritis in a resource-limited, real-world clinical setting: a prospective cohort study
    Arvind Ganapati
    Mahasampath Gowri
    Belavendra Antonisamy
    Debashish Danda
    Clinical Rheumatology, 2021, 40 : 1871 - 1879